Climb Bio Q2 2026 cash $239.2M; pipeline advances with CLYM116 Phase 2 initiation in Q3

Climb Bio, Inc.

Cash, cash equivalents, and marketable securities $239.2M as of June 30, 2026; raised ~$110M in private placement in April 2026, extending runway into H2 2028.
R&D expenses $9.7M (vs $6.6M YoY); G&A $5.6M (vs $4.1M YoY); other income $1.9M.
CLYM116 Phase 1 data to be presented at R&D Spotlight on Sept 3, 2026; Phase 2 trial in IgAN to start dosing in Q3 2026.
Budoprutug data expected from pMN, ITP, and SLE studies in Q4 2026; SC formulation data positive.
Appointed Breanna O'Reilly, Ph.D., to Board of Directors in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.